Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates
Raises $10M to close first tranche of $25M Financing
View HTML
Toggle Summary Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 Watertown, MA  –  September 10, 2009  –  Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough
View HTML
Toggle Summary Tetraphase Pharmaceuticals Completes Series A Financing to Support the Advancement of Breakthrough Synthetic Chemistry Platform Raises $15M to close second tranche of $25M Financing
Tetraphase Pharmaceuticals Completes Series A Financing to Support the Advancement of Breakthrough Synthetic Chemistry Platform Raises $15M to close second tranche of $25M Financing Tetraphase Pharmaceuticals Completes Series A Financing to Support the Advancement of Breakthrough Synthetic
View HTML
Toggle Summary Tetraphase Pharmaceuticals Formed to Advance Breakthrough, Harvard-Developed Synthesis Technology for New Antibiotics to Treat Drug-Resistant Bacterial Infections
Harvard University Office of Technology Development
View HTML